BIOMAT Database Logo BIOMAT Database Logo

In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. 1998

S Bautista, and H Vallès, and R L Walker, and S Anzick, and R Zeillinger, and P Meltzer, and C Theillet
Equipe Génome et Cancer UMR 5535 Centre National de la Recherche Scientifique, Centre de Recherche, Montpellier, France.

The AIB1 gene was isolated upon microdissection of the homogeneously staining regions observed in breast cancer cell lines. It was subsequently shown to map at a region at 20q12 that is frequently amplified in breast tumors. In a screen of breast tumor cell lines, of all the genes mapping to the region, AIB1 appeared to be the most consistently amplified and overexpressed. AIB1 shares homology with the SRC-1 family of nuclear receptor coactivators. It was found to interact in a ligand-dependent manner with the estrogen receptor (ER) and to result in increased levels of estrogen-dependent transcription. These properties could be of important biological significance in breast and ovarian cancerigenesis, and we were, therefore, interested in determining whether the amplification of the AIB1 gene was associated with a particular phenotype or subgroup in these tumors. We tested a population of 1157 breast and 122 ovarian tumors in which DNA amplification had been determined previously at 15 chromosomal locations. Amplification of the AIB1 gene was observed in 4.8% of breast cancers and 7.4% of ovarian cancers. In breast tumors, AIB1 was correlated with ER and progesterone receptor positivity, as well as with tumor size. Correlation was also observed with the amplification of MDM2 and FGFR1 genes, but interestingly, no correlation was found with the amplification of CCND1, which is known to be strongly associated with ER. Furthermore, analyzing at 20q12-q13 range, we show the existence of three amplification cores, represented by AIB3/AIB4, AIB1, and RMC20C001. AIB1 and CCND1 amplifications may, thus, represent two different subsets of ER-positive breast tumors.

UI MeSH Term Description Entries
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D011980 Receptors, Progesterone Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives. Progesterone Receptors,Progestin Receptor,Progestin Receptors,Receptor, Progesterone,Receptors, Progestin,Progesterone Receptor,Receptor, Progestin
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002874 Chromosome Mapping Any method used for determining the location of and relative distances between genes on a chromosome. Gene Mapping,Linkage Mapping,Genome Mapping,Chromosome Mappings,Gene Mappings,Genome Mappings,Linkage Mappings,Mapping, Chromosome,Mapping, Gene,Mapping, Genome,Mapping, Linkage,Mappings, Chromosome,Mappings, Gene,Mappings, Genome,Mappings, Linkage
D002890 Chromosomes, Human, Pair 20 A specific pair of GROUP F CHROMOSOMES of the human chromosome classification. Chromosome 20
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D005260 Female Females
D005784 Gene Amplification A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication. Amplification, Gene
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

S Bautista, and H Vallès, and R L Walker, and S Anzick, and R Zeillinger, and P Meltzer, and C Theillet
Association of steroid receptor coactivator AIB1 with estrogen receptor-alpha in breast cancer cells.
November 2001, Breast cancer research and treatment,
S Bautista, and H Vallès, and R L Walker, and S Anzick, and R Zeillinger, and P Meltzer, and C Theillet
Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu.
February 2001, Cancer research,
S Bautista, and H Vallès, and R L Walker, and S Anzick, and R Zeillinger, and P Meltzer, and C Theillet
Gene amplification and expression of the steroid receptor coactivator SRC3 (AIB1) in sporadic breast and endometrial carcinomas.
March 2001, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
S Bautista, and H Vallès, and R L Walker, and S Anzick, and R Zeillinger, and P Meltzer, and C Theillet
AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer.
August 1997, Science (New York, N.Y.),
S Bautista, and H Vallès, and R L Walker, and S Anzick, and R Zeillinger, and P Meltzer, and C Theillet
Endogenously expressed estrogen receptor and coactivator AIB1 interact in MCF-7 human breast cancer cells.
November 2000, Proceedings of the National Academy of Sciences of the United States of America,
S Bautista, and H Vallès, and R L Walker, and S Anzick, and R Zeillinger, and P Meltzer, and C Theillet
Coactivator AIB1 links estrogen receptor transcriptional activity and stability.
August 2004, Proceedings of the National Academy of Sciences of the United States of America,
S Bautista, and H Vallès, and R L Walker, and S Anzick, and R Zeillinger, and P Meltzer, and C Theillet
Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas.
February 1999, The American journal of pathology,
S Bautista, and H Vallès, and R L Walker, and S Anzick, and R Zeillinger, and P Meltzer, and C Theillet
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
March 2003, Journal of the National Cancer Institute,
S Bautista, and H Vallès, and R L Walker, and S Anzick, and R Zeillinger, and P Meltzer, and C Theillet
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.
May 2007, Nature genetics,
S Bautista, and H Vallès, and R L Walker, and S Anzick, and R Zeillinger, and P Meltzer, and C Theillet
Transferrin receptor is inversely correlated with estrogen receptor in breast cancer.
January 1986, Breast cancer research and treatment,
Copied contents to your clipboard!